Cybrexa Therapeutics Overview

  • Founded
  • 2017
Founded
  • Status
  • Private
  • Employees
  • 21
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $31.2M
Latest Deal Amount
  • Investors
  • 4

Cybrexa Therapeutics General Information

Description

Developer of oncology therapeutics designed for antigen-independent intracellular drug delivery. The company's therapeutics rapidly bring novel compounds with robust IP to pivotal studies, enable highly potent drugs and combination therapies that are currently limited by toxicity, and expand the efficacy of existing anticancer agents to larger, high unmet need populations, enabling physicians to improve patient outcomes and save lives by developing the next generation of cancer therapeutics.

Contact Information

Website
www.cybrexa.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Primary Office
  • 5 Science Park
  • 395 Winchester Avenue
  • New Haven, CT 06511
  • United States
+1 (860) 000-0000

Cybrexa Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cybrexa Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series B) 15-Nov-2021 $31.2M 000.00 Completed Clinical Trials - Phase 2
4. Debt - PPP 27-Apr-2020 00000 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B1) 20-Jun-2019 000.00 000.00 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 27-May-2017 $6.08M $6.78M 000.00 Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) $700K $700K 000 Completed Startup
To view Cybrexa Therapeutics’s complete valuation and funding history, request access »

Cybrexa Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 0,000,000 00.000000 00.0 00.0 00 00.0 0.000
To view Cybrexa Therapeutics’s complete cap table history, request access »

Cybrexa Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of oncology therapeutics designed for antigen-independent intracellular drug delivery. The company's therapeut
Drug Delivery
New Haven, CT
21 As of 2021
000.00
00000000000 000.00

000000 0

d tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercita
0000 000000000
Montreal, Canada
000 As of 0000
00000
0000 0000-00-00
00000000 00000

00000000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000 000000000
Middleton, WI
00 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cybrexa Therapeutics Competitors (34)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Repare Therapeutics Formerly VC-backed Montreal, Canada 000 00000 00000000 00000
00000000 Venture Capital-Backed Middleton, WI 00 000.00 0000000000 0 000.00
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
You’re viewing 5 of 34 competitors. Get the full list »

Cybrexa Therapeutics Executive Team (9)

Name Title Board Seat Contact Info
Per Hellsund Co-Founder, Chief Executive Officer, Board Member & President
Vishwas Paralkar Ph.D Chief Scientific Officer
Arthur DeCillis MD Acting Chief Medical Officer
Peter Glazer Ph.D Co-Founder & Chief Medical Advisor
Ranjit Bindra Ph.D Co-Founder & Chief Scientific Adviser
You’re viewing 5 of 9 executive team members. Get the full list »

Cybrexa Therapeutics Board Members (5)

Name Representing Role Since
John Houston Ph.D Self Board Member 000 0000
Kevin Didden Self Co-Founder & Chairman of the Board 000 0000
Kevin Rakin Self Co-Founder & Board Member 000 0000
Michael Grillo JD Self Board Member 000 0000
Per Hellsund Cybrexa Therapeutics Co-Founder, Chief Executive Officer, Board Member & President 000 0000
To view Cybrexa Therapeutics’s complete board members history, request access »

Cybrexa Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cybrexa Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Elm Street Ventures Venture Capital Minority 000 0000 000000 0
Cycle Venture Partners Venture Capital Minority 000 0000 000000 0
Connecticut Innovations Venture Capital Minority 000 0000 000000 0
HighCape Capital Growth/Expansion Minority 000 0000 000000 0
To view Cybrexa Therapeutics’s complete investors history, request access »

Ready to get started?

Request a free trial